Quantcast

Latest Factor VIII Stories

2009-08-26 08:45:00

LACHEN, Switzerland and HOBOKEN, N.J., Aug. 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with...

2009-08-07 07:30:00

WAYNE, N.J., Aug. 7 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate(R) FS, antihemophilic factor (recombinant). The new vial size offers greater convenience for patients with hemophilia A who require a higher dose. The 3000 IU vial may eliminate the need for combining smaller vials and may allow some patients to achieve more precise dosing. It is available...

2009-07-15 07:00:00

BOSTON, July 15 /PRNewswire/ -- Bayer HealthCare announced today the recipients of the 2009 World Federation of Hemophilia's International Hemophilia Nursing Fellowship. This Bayer-supported initiative provides hemophilia education and training to nurses in developing countries - areas where hemophilia-trained healthcare professionals are in short supply. Three recipients were selected out of a pool of 59 applications from eight countries. "Worldwide, about 70 percent of people with...

2009-07-14 06:30:00

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical...

2009-07-09 11:00:00

WAYNE, N.J., July 9 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals launched the BayCuff(TM) self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their caregivers. The centerpiece of the program is an adjustable cuff worn on the hand or arm that allows patients to practice the technique of self-injection without actually infusing themselves and helps caregivers learn to...

2009-04-17 07:30:00

BERKELEY, Calif., April 17 /PRNewswire/ -- In recognition of the 20th anniversary of World Hemophilia Day, Bayer HealthCare reaffirmed its commitment to the global hemophilia community by pledging euro 250,000 to the World Federation of Hemophilia (WFH). To mark this milestone, Bayer employees around the world will engage in activities to support the mission of this annual event - to increase awareness of and promote support for the needs of people living with hemophilia and other bleeding...

2009-04-06 09:41:00

New RNA therapy reversed hemophilia in mice GAITHERSBURG, Md., April 6 /PRNewswire/ -- VIRxSYS Corporation announced today the publication of a new research article, "Trans-splicing into Highly Abundant Albumin Transcripts for Production of Therapeutic Proteins In Vivo," in the journal Molecular Therapy. The study describes a novel RNA therapy technique in which an RNA molecule that is inserted into the albumin gene "hijacks" the albumin, causing it to produce the newly added gene's...

2009-02-19 07:00:00

NEW YORK, Feb. 19 /PRNewswire/ -- On Friday, February 13, 2009, Anna G. Eshoo (D-CA) and Jim Langevin (D-RI), along with Senators Byron Dorgan (D-ND) and Olympia Snowe (R-ME) introduced the Health Insurance Coverage Protection Act (H.R. 1085; S442). The legislation, introduced in both houses in 2008, will set a $10 million minimum lifetime cap on health insurance, with future increases based on inflation. The National Hemophilia Foundation (NHF) played a vital role in encouraging the...

2009-02-12 07:30:00

IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B LAGUNA NIGUEL, Calif., Feb. 12 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., today announced the initiation of a Phase 1 clinical trial of IB1001, an intravenous (IV) recombinant Factor IX (rFIX) product for control and prevention of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies to treat this disorder is in excess of $600 million. The...

2009-02-04 09:17:00

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A. Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.